X0306 4 2019-05-09 0 0001563880 Trevi Therapeutics, Inc. TRVI 0001237289 SANDELL SCOTT D 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 0 0 1 0 Common Stock 2019-05-09 4 C 0 1938562 A 1938562 I See Note 2 Common Stock 2019-05-09 4 P 0 1000000 10.00 A 2938562 I See Note 2 Common Stock 2019-05-09 4 P 0 1500000 10.00 A 4438562 I See Note 2 Series C Preferred Stock 2019-05-09 4 C 0 17099315 0.00 D Common Stock 1938562 0 I See Note 2 On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest. Acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 6, 2019 with a closing date of May 9, 2019. /s/ Sasha Keough, attorney-in-fact 2019-05-13